Table 4.
Showing comparison of clinical outcomes of COVID-19 patients with DKA (and combined DKA/HHS) in whom individual patient data were available (N = 27).
| Parameter | Discharged (n = 17) | Deceased (n = 10) | p value |
|---|---|---|---|
| Age (years) | 46.0 (33.5–54.0) | 42.5 (34.2–59.7) | 1.000 |
| Sex | Male = 11 | Male = 10 | – |
| Female = 6 | Female = 0 | ||
| DKA vs. Combined DKA/HHS | DKA = 15 (71%) | DKA = 6 (29%) | – |
| DKA/HHS = 2 (33%) | DKA/HHS = 4 (67%) | ||
| Blood glucose (mg/dl) | 463.0 (347.0–641.0) | 801.5 (376.5–1080.5) | 0.120 |
| pH | 7.23 (7.09–7.26) | 7.00 (6.91–7.11) | 0.017 |
| Bicarbonate (mmol/l) | 10.4 (6.0–15.0) | 7.0 (5.7–8.0) | 0.098 |
| Anion gap (mEq/l) | 25.5 (16.8–34.0) | 29.0 (28.0–30.5) | 0.806 |
COVID-19: Novel coronavirus disease; DKA: Diabetic ketoacidosis; HHS: Hyperglycemic hyperosmolar syndrome.